Listen to the article
In a significant development for the millions of patients taking popular weight-loss and diabetes medications, new research suggests GLP-1 drugs like Ozempic and Wegovy may increase the risk of bone fractures in older adults, raising concerns about their long-term safety profile.
A study published in February in the Journal of Clinical Endocrinology & Metabolism found that older adults with type 2 diabetes who began GLP-1 medication regimens faced an 11% higher risk of fragility fractures compared to those taking other diabetes treatments. While the percentage increase may seem modest, researchers stress its significance for an already vulnerable population.
“Both older age and type 2 diabetes are independent risk factors for fragility fractures,” explained Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel and the study’s lead author. “This is a population that deserves special attention.”
Fragility fractures, which occur from minor falls or even routine activities, often indicate underlying osteoporosis and can lead to hospitalization, loss of independence, and increased mortality rates among older adults. The comprehensive study tracked more than 46,000 adults aged 65 and older for nearly three years, with data showing a statistically significant increase in fracture risk among GLP-1 users after adjusting for other factors.
The findings represent a shift from earlier research. Previous studies examining older generations of GLP-1 medications in younger patients didn’t demonstrate increased fracture risks. However, newer and more potent formulations are now widely prescribed to older demographics, potentially changing the risk landscape.
“In older adults treated with contemporary medications, the fracture risk picture looks different and warrants close attention,” Kasher Meron noted.
The Israeli study comes amid mounting evidence of potential bone health concerns associated with these widely prescribed drugs. Separate research presented at the American Academy of Orthopaedic Surgeons’ annual meeting this month revealed that among 146,000 adults with obesity and type 2 diabetes, GLP-1 users had a 29% higher relative risk of osteoporosis over five years compared to non-users.
The same analysis found slightly elevated rates of gout among GLP-1 users – 7.4% versus 6.6% in non-users, representing a 12% relative increase. Cases of osteomalacia, a condition causing bone softening, were rare but occurred approximately twice as often in those taking GLP-1 medications.
Medical experts point to several potential mechanisms behind these observations. GLP-1 medications work partly by suppressing appetite, often leading to significant weight loss. While beneficial for many health markers, rapid weight reduction can decrease mechanical loading on the skeleton – a principle similar to what happens to astronauts in zero-gravity environments.
“It’s the same idea as when we always hear about astronauts going up into space, and they’re in a gravity-zero environment for too long,” explained Dr. John Horneff, associate professor of orthopedic surgery at the University of Pennsylvania and lead author of the orthopedic conference presentation. “There’s nothing forcing their bones to kind of hold their weight anymore. And a lot of those astronauts come back with low bone density.”
Nutritional factors may also play a role. The decreased caloric intake associated with GLP-1 use might result in reduced consumption of bone-essential nutrients like calcium, vitamin D, and protein. Additionally, the rapid tissue breakdown during accelerated weight loss can temporarily increase uric acid levels, potentially explaining the observed uptick in gout cases.
Despite these findings, researchers emphasize that the studies are observational and show association rather than causation. The benefits of GLP-1 medications – including improved blood sugar control, weight management, and reduced cardiovascular risk – remain substantial for many patients.
Novo Nordisk, manufacturer of leading GLP-1 medications including Ozempic and Wegovy, maintains that patient safety is a priority. Company spokesperson Liz Skrbkova noted that the known risks and benefits are reflected in FDA-approved labeling, adding that semaglutide (the active ingredient) has demonstrated cardiovascular, kidney, and liver benefits when used under medical supervision.
“Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors,” Skrbkova added.
Medical experts now recommend that healthcare providers assess bone health before initiating GLP-1 treatment in older patients, particularly through bone density screening. For those already taking these medications, adequate nutrition and resistance training may help preserve muscle and bone strength during weight loss.
“Bone health should be assessed before starting these medications in older patients — not as an afterthought,” Kasher Meron advised.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
11 Comments
As someone who has struggled with weight, I’m disappointed to hear about these potential side effects of GLP-1 drugs. While the promise of effective weight loss is enticing, patient safety has to be the top priority. I hope the industry and regulators take these findings very seriously.
This is an important study that highlights the need for continued post-marketing surveillance of new drug classes like GLP-1 agonists. While they can be effective for weight loss, the potential for serious side effects like fractures and gout shouldn’t be overlooked.
As someone who covers the pharmaceutical industry, I’ll be keeping a close eye on how this issue develops. The safety profile of these popular weight loss drugs seems more complex than initially thought. Patients and doctors deserve to have all the facts before making treatment decisions.
I’m curious to see if this finding holds up in further studies. While the 11% increased risk seems modest, it could still have significant public health implications given how widely these weight loss drugs are prescribed. Fractures can be very debilitating, especially for older adults.
That’s a good point. Even a seemingly small increase in fracture risk could translate to many more hospitalizations and lost independence if these medications are widely used. Ongoing safety monitoring will be critical.
In addition to the fracture risk, the association with gout is also quite concerning. Gout can be extremely painful and disabling. The overall safety profile of these GLP-1 drugs appears to be more complicated than initially thought.
Agreed, the potential link to gout is another worrying aspect. These medications may have more widespread effects on metabolism and inflammation than was previously understood. Careful patient monitoring will be essential.
This is really concerning news about the potential side effects of GLP-1 weight loss drugs. Increased fracture risk and osteoporosis could be very serious for older patients already vulnerable to these conditions. More research is needed to fully understand the long-term safety profile of these medications.
You’re right, the increased fracture risk is quite worrying. Doctors will need to carefully weigh the benefits and risks for each patient, especially the elderly, when prescribing these GLP-1 drugs.
The association with osteoporosis is particularly worrying, given that many older adults already have issues with bone density. If these medications are impacting bone health, that could lead to a lot of preventable fractures and loss of mobility. More research is clearly needed.
Absolutely. Preserving bone health and preventing fractures should be a key consideration, especially in the elderly population. The potential tradeoffs with these weight loss drugs need to be very carefully evaluated.